Comparison of heparin therapy for 48 hours in unstable angina pectoris.
Explore this paper's citation graph
Summary
The results suggest that the optimal duration of heparin therapy is up to 48 hours after admission in unstable angina; a longer time period is associated with increased adverse consequences.
- Type
- article
- Published
- 1997-02-01
- Cited by
- 12
- References
- 18
- OpenAlex
- https://openalex.org/W2148502715
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:44950532
Keywords
Medicine, Heparin, Myocardial infarction, Unstable angina, Aspirin
References
- Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.
- Unstable angina : diagnosis and management
- Angiography in unstable angina.
- Risk stratification in unstable angina. Prospective validation of the Braunwald classification.
- Effect of maximal medical therapy on refractoriness of unstable angina pectoris.
- Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).
- Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990
- Does the AHA/ACC task force grading system predict outcome in multivessel coronary angioplasty?
- Antiplatelet and antithrombotic therapy in unstable angina.
- Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994
- Immediate and follow-up results of the conservative coronary angioplasty strategy for unstable angina pectoris.
- Morphological and quantitative angiographic analyses of progression of coronary stenoses. A comparison of Q-wave and non-Q-wave myocardial infarction.
- Early percutaneous transluminal coronary angioplasty in the management of unstable angina.
- Emergency coronary angioplasty in refractory unstable angina.
- Aspirin, heparin, or both to treat acute unstable angina.
- Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study.
- Comparison of Medical and Surgical Treatment for Unstable Angina Pectoris
- Unstable Angina A Classification
Cited by
- Antithrombin activity during the period of percutaneous coronary revascularization: relation to heparin use, thrombotic complications and restenosis.
- Unstable angina pectoris.
- Antithrombotic and thrombolytic therapy in acute cardiac care.
- Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?
- Redefining medical treatment in the management of unstable angina.
- Role of prolonged intravenous heparin in unstable angina patients prior to coronary angioplasty.
- Acute Coronary Syndrome
- Recent advances in the management of unstable angina and non-Q-wave myocardial infarction.
- Akute Koronarsyndrome – ein Update Teil I: Pathogenese und medikamentöse Therapie
- Blood pressure and death from coronary heart disease.
- The second part of our special feature discusses established and newer treatments for myocardial infarction and angina Myocardial infarction and angina Current drug therapy
- Therapie der instabilen Angina
Related papers
- Heparin assay and protamine titration.
- Spontaneous platelet aggregation in heparin-treated patients.
- The Showing and Curative Effect Assess of the Color Doppler flow Imaging in Different Periods of Deep Vein Thrombus in Legs
- Heparin Releasing Rate Evaluation of Heparin Coated Modified Polyvinyl Chloride Material
- The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
- Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients
- Study of heparin stability on heparin-coated circuits under simulating cardiopulmonary bypass
- A numerical study of the effect of thrombus breakdown on predicted thrombus formation and growth